House Committee Calls for CMS Action on Biosimilars

“‘One of the ways to align these incentives would be for CMS, in particular the Center for Medicare & Medicaid Innovation, to launch a demonstration project, a shared savings program in Medicare Part B for biosimilars. This would reward physicians for increasing their utilization of biosimilars, which would both create that incentive for physicians and align that incentive with the desire of taxpayers to lower overall costs in the biologic spend category,’ [Alex Brill] said.”

Maybe Every Good Turn Deserves A Tax Break

“The result of those changes is a 4 percent dip in total charitable giving, and, ‘for middle- to upper-middle-income tax filers, the doubling of the standard deduction is responsible for nearly all the change in giving,’ Alex Brill and Derrick Choe, both of the American Enterprise Institute, explained in a 2018 analysis.”

Shared Savings Models Could Yield Part B Savings

“The establishment of a shared savings model has the potential to increase health care savings, biologic competition, and biosimilar utilization if implemented in Medicare Part B, according to Alex Brill, founder of Matrix Global Advisors (MGA) and a resident fellow at the American Enterprise Institute (AEI), who makes the case in a new research paper.”

New Belgium Brewery’s employees think like owners. Because they are.

Alex Brill was quoted in Fast Company for his research on tax policy effects on business:

“… [Brill] has found that employees in ESOPs “get better at the job, and instead of quitting as soon as they get skills, they stay and get more skills.” Companies with ESOPs require fewer managers, as AEI’s Brill discovered in his research, because workers are given more freedom and are better able to manage themselves.”

Debate Over Whether Biologics Constitute Natural Monopolies Continues

“Peter B. Bach, MD, a well-known critic of high drug prices, along with Jennifer A. Ohn, MPH, Preston Atteberry, MD, and Mark Trusheim, MSc, first wrote in April that biosimilar competition is an economically inefficient way to achieve the goal of lower prices; the biosimilar environment is different than the one that exists in the generic marketplace for small-molecule drugs. These authors said, instead, that biosimilars are natural monopolies and as such need price regulation in order for them to succeed and for prices to come down.”